Long survival in sickle cell anemia.

Area of Science:

• Hematology
• Genetics
• Clinical Medicine

Background:

• Sickle cell anemia (SCA) is a genetic blood disorder with significant morbidity and mortality.
• Understanding factors influencing long-term survival in SCA is crucial for patient management.

Purpose of the Study:

• To compare hematologic, biochemical, and clinical parameters between SCA patients who survived beyond 40 years and those who died before 40.
• To identify potential factors associated with increased longevity in sickle cell anemia.

Main Methods:

• Retrospective comparison of two groups of sickle cell anemia patients: long-term survivors (>40 years) and short-term survivors (<40 years).
• Analysis of hematologic data (anemia, hemolysis, HbA2, fetal hemoglobin), biochemical markers (red cell zinc), clinical parameters (crises, complications), and genetic factors (alpha/beta chain synthesis, alpha gene mapping).

Main Results:

• No significant differences in anemia severity, hemolysis, or hemoglobin A2 levels between groups.
• Long-term survivors showed higher levels of fetal hemoglobin, increased red cell zinc, and better-developed secondary sexual characteristics.
• Long-term survivors experienced fewer crises but had higher rates of leg ulcers, congestive heart failure, and aseptic necrosis; cerebrovascular accidents were absent in this group, contrasting with 9/11 short survivors.

Conclusions:

• Fetal hemoglobin levels, red cell zinc status, and secondary sexual characteristics appear to be associated with longer survival in sickle cell anemia.
• While long-term survivors avoid early cerebrovascular events, they face a higher burden of chronic organ damage.
• The precise impact of zinc and elevated fetal hemoglobin on sickle cell anemia longevity requires further investigation.